RUNX3 regulates renal cell carcinoma metastasis via targeting miR-6780a-5p/E-cadherin/EMT signaling axis
Metrics: PDF 1664 views | HTML 1710 views | ?
Feifei Chen1,*, Xin Liu1,5,*, Qian Cheng2, Shudong Zhu4, Jin Bai1 and Junnian Zheng2,3
1Jiangsu Cancer Biotherapy Institute, Xuzhou Medical College, Xuzhou, Jiangsu, P.R. China
2Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College, Xuzhou, Jiangsu, China
3Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, China
4State Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, China
5Department of Urology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, China
*These authors have contributed equally to this work
Junnian Zheng, email: email@example.com
Jin Bai, email: firstname.lastname@example.org
Shudong Zhu, email: email@example.com
Keywords: RUNX3; renal cell carcinoma; tumor suppressor; E-cadherin; miR-6780a-5p
Received: November 26, 2015 Accepted: July 06, 2016 Published: November 08, 2017
Runt-related transcription factor 3 (RUNX3) is a tumor suppressor in many human solid tumors. In this study, renal cell carcinoma (RCC) microarray analysis showed that the level of RUNX3 expression was lower in RCC tissue than in adjacent normal renal tissues, and was correlated with depth of invasion (pT stage) (P<0.001) and Tumor Node Metastasis (TNM) stage (P<0.001). RUNX3 expression was negatively correlated with poor 5-year overall and disease-free patient survival. RUNX3 suppressed RCC metastasis and invasion and increased levels of E-cadherin, an important marker of epithelial-mesenchymal transition, in vitro and in vivo. RUNX3 also inhibited microRNA-6780a-5p, which directly targeted the E-cadherin 3’untranslated region and decreased its expression. We confirmed that miR-6780a-5p mimics abrogated RUNX3-mediated E-cadherin upregulation and RCC metastasis/invasion inhibition. Thus, RUNX3 targeted the miR-6780a-5p/E-cadherin/EMT signaling axis to suppress renal carcinoma cell migration and invasion. This pathway illustrates a new RUNX3 function and provides potential targets for the treatment of RUNX3 mutant and loss-of-function RCC tumors. RUNX3 may also act as an effective prognostic indicator in RCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.